Difference between revisions of "HP802-247"
(Created page with "{{Construction Site}} HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin wil...") |
m |
||
| Line 1: | Line 1: | ||
| − | + | HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb | |
| − | + | | last= | |
| − | HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref> | + | | first= |
| − | {{ | + | | date=2012-08-03 |
| − | | url = http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | + | | title=Spray-on-skin' treatment for leg ulcers |
| − | | | + | | url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx |
| − | | accessdate = 2012-11-24 | + | | publisher=NHS |
| − | + | | accessdate=2012-11-24 | |
| − | + | }}</ref> | |
| − | }} | ||
| − | </ref> | ||
== HP802-247 == | == HP802-247 == | ||
| − | |||
The new spray (HP802-247) consisted of a combination of donated skin cells and proteins. | The new spray (HP802-247) consisted of a combination of donated skin cells and proteins. | ||
| − | The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref> | + | The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb |
| − | {{ | + | | last= |
| − | | | + | | first= |
| − | | title = Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial | + | | date=201209 |
| − | | | + | | title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial |
| − | | | + | | url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract |
| − | | | + | | publisher=The Lancet |
| − | }} | + | | accessdate=2012-11-24 |
| − | </ref> | + | }}</ref> |
The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials. | The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials. | ||
| − | + | {{REF}} | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
[[Category:Foreskin Products]] | [[Category:Foreskin Products]] | ||
| Line 38: | Line 30: | ||
[[Category:CircLeaks]] | [[Category:CircLeaks]] | ||
| − | |||
[[Category:From IntactWiki]] | [[Category:From IntactWiki]] | ||
Revision as of 19:49, 18 August 2019
HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.[1]
HP802-247
The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.
The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.[2]
The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.
References
- ↑
(3 August 2012). Spray-on-skin' treatment for leg ulcers
, NHS. Retrieved 24 November 2012. - ↑ (November 2024).
Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
, The Lancet. Retrieved 24 November 2012.
